What is the actual cost of larotinib/larlotinib after medical insurance reimbursement in 2025?

Larotrectinib is a new type of targeted therapy drug mainly used to treat solid tumors carrying neurotrophic tyrosine receptor kinase (NTRK) gene fusion. . In recent years, with the increasing emphasis on and demand for precision treatment, larotrectinib has gradually gained recognition in the Chinese market and has recently been officially included in medical insurance reimbursement. The implementation of this policy allows more and more patients to receive this effective treatment at a lower financial burden.

Without medical insurance reimbursement, the price of larotrectinib is relatively high. Taking the capsule preparation with the specifications of 100mg*56 capsules as an example, its market retail price is about 20,000 yuan. In addition, the price of another oral solution preparation with specifications of 50ml:1.0g*2 bottles is also high. However, the addition of medical insurance has greatly improved patients' medication burden, allowing patients to enjoy partial reimbursement of costs when receiving treatment.

The specific medical insurance reimbursement ratio varies by region and hospital. In some tertiary hospitals in big cities, patients may enjoy a higher proportion of reimbursement, while in rural hospitals or primary medical institutions, the reimbursement policy may be different. Therefore, before using larotrectinib, patients are advised to consult the local hospital pharmacy to obtain the most accurate medical insurance reimbursement information. Generally speaking, reimbursement from medical insurance can cover part of the cost of drugs, thereby reducing the patient's out-of-pocket amount, which greatly relieves the patient's financial pressure.

Calculated based on actual costs, assuming a patient purchases 100mg*56 larotinib capsulesif the medical insurance reimbursement ratio is 50%, the patient will have to pay out-of-pocket expenses of about 10,000 yuan. At the same time, during the use of drugs, patients also need to consider related expenses such as regular review and other auxiliary treatments, which also affect the patient's overall treatment cost to a certain extent.

Reference materials:https://www.vitrakvi.com/